News and insights
223 81 Lund, Sverige
+46 46-15 21 00
Clinical Laserthermia Systems (CLS) is listed on Nasdaq First North Growth Market. Our aim is to provide relevant and transparent information for analysts, investors and media with the latest financial reports, events, news and the development of CLS’s share.
Information och domument inför CLS extra bolagsstämma 2022 finns här.
CLS’ vision is that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to surgery for several patient groups. CLS’ treatment systems provide minimally invasive treatment for solid soft tissue tumors of the prostate and brain as well as for the treatment of epilepsy.
CLS’ use of laser ablation as a focal therapy is a high precision alternative that is safe and has fewer and less serious side effects than drugs and traditional surgery. In the USA and Europe alone, the current market for the minimally invasive treatment of prostate cancer is valued at over USD 35 billion with the global markets for the other indications targeted by CLS – glioblastoma and epilepsy – expected to be worth in excess of USD 7 billion by 2027.
2022-11-22 Extraordinary General Meeting 2022
2023-02-23 Year-end Report 2022
2023-05-19 Interim Report 1/23 January – March
2023-06-29 Annual General Meeting
2023-08-25 Interim Report 2/23 January – June
2023-11-17 Interim Report 3/23 January – September
2024-02-23 Year-end Report 2023
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region